Prostatype Genomics announces final outcome of the Rights Issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.
Prostatype Genomics announces final outcome of the Rights Issue
Prostatype Genomics AB (”Prostatype Genomics” or the “Company”) today announces the final outcome of the issue of shares and warrants (“Units”) with preferential rights for the Company’s existing shareholders (the “Rights Issue”) which ended on January 5, 2024. The final outcome shows that 62,480,496 Units, corresponding to approximately 52,3 percent of the Rights Issue, were subscribed for with and without the exercise of Unit rights. The Rights Issue was covered by subscription commitments corresponding to approximately 45.0 percent, which means that no subscription commitments will take effect. The Company receives proceeds amounting to approximately SEK 25,0 million (before costs attributable to the Rights Issue), of which SEK 1.2 million will be received through set-off of debts and thus not be provided to the Company in cash. Upon full exercise of all TO3 warrants, the company will receive proceeds amounting to, at a minimum, an additional SEK 2.5 million, dependant upon the final exercise price.
”We are grateful for the continued support that existing and new investors have shown us in this capital raise, despite the challenging market conditions. The capital raised will be invested in value-generating activities, primarily in the US where our validation study continues to generate more data for the Prostatype test day by day which is of great importance. We look forward to continuing our hard work to generate value for the healthcare sector and prostate cancer patients around the world as well as for our shareholders”, says Fredrik Persson, CEO Prostatype Genomics.
The subscription period of the Rights Issue ended on January 5, 2024, and the final outcome shows that 53,615,227 Units, corresponding to approximately SEK 21.4 million or approximately 44.9 percent of the Rights Issue, were subscribed for through the exercise of Unit rights. An additional 8,865,269 Units were subscribed for without the exercise of Unit rights, corresponding to approximately SEK 3.5 million or approximately 7.4 percent of the Rights Issue. In total, 62,480,496 units were subscribed for with and without the exercise of Unit rights, corresponding to approximately SEK 25.0 million or approximately 52.3 percent of the Rights Issue. The Company receives proceeds amounting to approximately SEK 25.0 million (before costs attributable to the Rights Issue), of which SEK 1.2 million will be received through set-off of debts and thus not be provided to the Company in cash.
Units subscribed for without the exercise of Unit rights will be allocated according to the principles set out in the prospectus published by the Company on December 11, 2023. Settlement notes will be distributed after January 9, 2024. The subscribed and allocated Units must be paid in cash according to the instructions on the settlement note. Shareholders registered with a nominee will be notified of their allocation in accordance with the nominee’s procedures.
Share capital and number of shares
Through the Rights Issue, the share capital in the Company increases by SEK 6,248,049.60, from SEK 1,194,600.07 to SEK 7,442,649.67, through the issuance of 624,804,960 shares. The number of shares thus increases from 119,460,007 to 744,264,967 shares. The dilution amounts to 83.9 percent. Upon full exercise of all TO3 warrants, the share capital will increase by an additional SEK 2,499,219.84, from SEK 7,442,649.67 to SEK 9,941,869.51, through the issuance of 249,921,984 shares. The number of shares thereby increases from 744,264,967 to 994,186,951 shares. The dilution amounts to 25.1 percent.
Trading in BTU
Trading in paid subscribed units (“BTU”) will be conducted on Nasdaq First North Growth Market until the week after the Rights Issue has been registered with the Swedish Companies Registration Office. Such registration is expected to take place around week 3, 2024.
Warrants
Subscribers of Units in the Rights Issue will receive four (4) warrant of series 3 free of charge. One (1) warrant of series 3 entitles the holder to subscribe for one (1) new share. The subscription price for the warrant of series 3 will be set at 70 percent of the volume-weighted average price ("VWAP") during the measurement period March 14–28, 2024, but at a minimum of SEK 0.01 (corresponding to the quota value). Warrants of series 3 can be exercised to subscribe for shares in Prostatype Genomics during the period April 5–19, 2024. The warrants will be listed on Nasdaq First North Growth market after registration of the Rights Issue with the Swedish Companies Registration Office.
Advisors
Prostatype Genomics has mandated Penser By Carnegie and Advokatfirman Lindahl as financial and legal advisors respectively in connection with the Rights Issue.
For further information about Prostatype Genomics, please contact:
Telephone: +46 (0) 73 049 77 01.
e-mail: fredrik.persson@prostatypegenomics.com
Certified Adviser
Carnegie Investment Bank AB (publ), +46 (0)73 856 4265, certifiedadviser@carnegie.se
This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-01-2024 [08]:[00] CET.
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer to sell or an offer to buy or subscribe for shares issued by the Company in any jurisdiction where such offer or invitation would be illegal. In a member state within the European Economic Area ("EEA"), securities referred to in the press release may only be offered in accordance with applicable exemptions under Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation").
This press release is not an offer or invitation to acquire or subscribe for shares or other securities in the United States. The securities that have been mentioned in this release may not be sold in the United States without registration, or without application of an exception from registration, according to the applicable U.S. Securities Act from 1933 ("Securities Act"), or as a part of a transaction that is not covered by the registration requirements according to the Securities Act. There is no intention to register any shares or securities mentioned herein in the United States or to announce a public offering of such securities in the United States. The information in this press release may not be published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Japan, Canada, Hong Kong, New Zealand, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction in which the release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would demand additional registration or other actions according to Swedish law. Acts in contrary to this instruction may constitute a crime according to applicable securities laws.
This release is not a prospectus in accordance to the definition in the Prospectus Regulation as has not been approved by any regulatory authority. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the prospectus. Thus, investors are encouraged to review the prospectus in its entirety. This press release constitutes an advertisement in accordance with article 2 k of the Prospectus Regulation. Prostatype Genomics has not authorized any offer to the public of shares or rights in any other member state of the EEA than Sweden. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares. An investment decision to acquire or subscribe for shares in the Rights Issue shall only be made based on publicly available information.
To the extent this press release contains forward-looking statements, such statements does not constitute facts and are characterized by words such as "shall", "expect", "believe" "assess", "intend", "estimate" and similar expressions. Such statements reflect Prostatype Genomics's intentions, views or present expectations or assumptions. Such forward-looking statements are based on Prostatype Genomics's current plans, estimates and projections, which have been made to the best of Prostatype Genomics's ability. However, Prostatype Genomics does not assert that these statements will be correct in the future. Forward-looking statements are associated with risks and uncertainties which are difficult to predict and which generally cannot be affected by Prostatype Genomics. It should be contemplated that actual events or outcomes may differ materially from what is included or expressed in such forward-looking statements.